Drug intelligence / Profile preview

Bacteroides salyersiae CSP6

Development stage: Preclinical
Lead developer: Ocean University of China
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bacteroides salyersiae CSP6 is a next-generation probiotic bacterium isolated from the fecal sample of a healthy Chinese individual. It is a commensal species from the human gut microbiota with demonstrated anti-colitis properties. The bacterium works by reshaping the colonic microbiota, decreasing pathogenic Escherichia-Shigella spp. and increasing beneficial probiotic species including Dubosiella spp. and Bifidobacterium pseudolongum. Through these microbiota changes, it increases fecal concentrations of anti-inflammatory metabolites including equol, 8-deoxylactucin, and tiglic acid. B. salyersiae CSP6 is also a potent chondroitin sulfate-degrading species. Developed by researchers at Ocean University of China, School of Medicine and Pharmacy.

Other names: B. salyersiae CSP6

Beyond the preview

Go deeper on Bacteroides salyersiae CSP6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacteroides salyersiae CSP6.

Explore the full profile